Avsola

Manufacturer:

Amgen

Name:

Avsola

HCPCS Code Descriptor:

Injection, infliximab-axxq, biosimilar, (avsola), 10 mg

Category:

Q Code

HCPCS:

Q5121

NDC(s):

55513-0670-01

Primary Type:

Immunology Anti-TNF Biosimilar

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

Avsola is an Immunology Anti-TNF Biosimilar drug manufactured by Amgen and administered via the Intravenous route of administration. The Q Code: Q5121 is aligned to the drug Avsola.

Avsola works by binding to tumor necrosis factor alpha and preventing it from performing certain processes. Avsola is used to treat a variety of autoimmune disorders. This medication is manufactured by Amgen and is a biosimilar to the medication Remicade (J1745). Avsola was aligned to the HCPCS code Q5121 in July 2020. Patient assistance programs for this medication can be found through the Amgen Safety Net Foundation.